Embedded Files
DelveInsight's "Allergic Rhinitis Pipeline Insight 2025" report offers detailed insights on 35+ companies and 35+ pipeline drugs within the Allergic Rhinitis pipeline arena. It encompasses Allergic Rhinitis Pipeline drug profiles, including clinical and nonclinical stage products. It also evaluates Allergic Rhinitis Pipeline Therapeutics by product type, stage, route of administration, and molecule type. Additionally, it emphasizes inactive pipeline products in this area.
DelveInsight's "Allergic Rhinitis Pipeline Insight 2025" report offers detailed insights on 35+ companies and 35+ pipeline drugs within the Allergic Rhinitis pipeline arena. It encompasses Allergic Rhinitis Pipeline drug profiles, including clinical and nonclinical stage products. It also evaluates Allergic Rhinitis Pipeline Therapeutics by product type, stage, route of administration, and molecule type. Additionally, it emphasizes inactive pipeline products in this area.
Interested in the newest developments in the Allergic Rhinitis Pipeline? Explore the therapies and trials gaining attention @ Allergic Rhinitis Pipeline Outlook Report
Key Takeaways from the Allergic Rhinitis Pipeline Report
On September 16, 2025, Advagene Biopharma Co. Ltd. revealed a trial to evaluate the safety, tolerability, and effectiveness of three doses of AD17002 compared to placebo. Participants will be assigned randomly at 3:1 ratios in each of three groups to receive AD17002 or placebo.
DelveInsight's Allergic Rhinitis Pipeline report illustrates a vibrant landscape with 35+ active participants advancing 35+ pipeline therapies for Allergic Rhinitis management.
The prominent Allergic Rhinitis Companies include Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma, and others.
Promising Allergic Rhinitis Therapies such as GSK256066, Azelastine Hydrochloride, Fluticasone Furoate Nasal Spray, Stapokibart Injection, CM310, MK0476, Loratadine, FEX60/PE10, and others.
Eager to learn which firms are driving advancements in Allergic Rhinitis? Explore the comprehensive pipeline details @ Allergic Rhinitis Clinical Trials Assessment
The Allergic Rhinitis Pipeline Report delivers a disease summary, pipeline overview, and therapeutic evaluation of key pipeline therapies in this field. The Allergic Rhinitis Pipeline Report also underscores unmet needs related to Allergic Rhinitis.
Allergic Rhinitis Overview
Allergic Rhinitis (AR) is an atopic condition manifesting with symptoms like sneezing, nasal blockage, clear nasal discharge, and nasal itching. It involves an IgE-mediated immune reaction to airborne allergens in the initial phase, followed by a leukotriene-driven later phase. It impacts one in six people and links to considerable discomfort, productivity loss, and medical expenses. Traditionally, AR was seen as a nasal-only issue, but the unified airway concept now views it as part of a broader allergic response, connected to conditions like asthma and atopic dermatitis with shared underlying mechanisms.
Allergic Rhinitis Emerging Drugs
REGN5713-5714-5715: Regeneron Pharmaceuticals
REGN5713-5714-5715 consists of three Bet v1 monoclonal antibodies. Regeneron Pharmaceuticals is exploring REGN5713-5714-5715 via intravenous administration in Phase III trials for allergic rhinitis and conjunctivitis.MM09-MG01: Immunotek
Immunotek is advancing a subcutaneously delivered immunotherapy product MM09, featuring biological extracts of house dust mite, known as M601 (MM09-MG01). A Phase III randomized, placebo-controlled, multicenter study with three active groups versus one placebo group aims to assess efficacy and safety of subcutaneous immunotherapy in individuals with mild to moderate asthma and allergic rhinitis/rhinoconjunctivitis (intermittent or persistent) due to house dust mite sensitivity (Dermatophagoides pteronyssinus and/or D. farinae) and grass pollen.
If you're monitoring current Allergic Rhinitis Clinical trials, this update is essential. Discover the innovations @ Allergic Rhinitis Treatment Drugs
The Allergic Rhinitis Pipeline report provides insights into:
The report offers in-depth information on companies creating therapies for Allergic Rhinitis, including the total therapies per company.
It evaluates various therapeutic candidates divided into early, mid, and late development stages for Allergic Rhinitis treatment.
Allergic Rhinitis Companies are engaged in targeted therapeutics development with corresponding active and inactive (dormant or discontinued) projects.
Allergic Rhinitis Drugs in development, classified by development stage, route of administration, target receptor, monotherapy or combination therapy, distinct mechanisms of action, and molecular type.
Comprehensive review of partnerships (corporate-corporate and corporate-academic), licensing deals, and funding details to promote future Allergic Rhinitis market progress.
Allergic Rhinitis Companies
Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma, and others.
Allergic Rhinitis Pipeline report evaluates the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under various ROAs such as:
Oral
Parenteral
Intravitreal
Subretinal
Topical
Allergic Rhinitis Products are classified under various Molecule types such as:
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
From novel drug prospects to competitive analysis, the Allergic Rhinitis Pipeline Report includes everything—review it today @ Allergic Rhinitis Market Drivers and Barriers, and Future Perspectives
Scope of the Allergic Rhinitis Pipeline Report
Coverage: Global
Allergic Rhinitis Companies: Poxel, Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals, Inc., Revolo Biotherapeutics, Emergo Therapeutics, Inc., Advagene Biopharma, AOBiome LLC, H. Lundbeck A/S, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Array Biopharma, Siolta Therapeutics, ASIT biotech, HAL Allergy Group, Worg Pharmaceuticals, ILTOO Pharma, and others.
Allergic Rhinitis Therapies: GSK256066, Azelastine Hydrochloride, Fluticasone Furoate Nasal Spray, Stapokibart Injection, CM310, MK0476, Loratadine, FEX60/PE10, and others.
Allergic Rhinitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Allergic Rhinitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Remain informed in Healthcare Research—uncover upcoming trends in the Allergic Rhinitis Treatment landscape through this thorough review @ Allergic Rhinitis Emerging Drugs and Major Players
Table of Contents
Introduction
Executive Summary
Allergic Rhinitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
REGN5713-5714-5715: Regeneron Pharmaceuticals
Drug profiles in the detailed report.....
Mid Stage Products (Phase II)
IRL201104: Revolo Biotherapeutics
Drug profiles in the detailed report.....
Pre-clinical and Discovery Stage Products
Drug profiles in the detailed report.....
Inactive Products
Allergic Rhinitis Key Companies
Allergic Rhinitis Key Products
Allergic Rhinitis- Unmet Needs
Allergic Rhinitis- Market Drivers and Barriers
Allergic Rhinitis- Future Perspectives and Conclusion
Allergic Rhinitis Analyst Views
Allergic Rhinitis Key Companies
Appendix
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us
Contact Us
Kanishk
Page updated
Google Sites
Report abuse